NVCT · Nuvectis Pharma, Inc.
$23.48
+0.13 (+0.56%)
At close · Aug 21
Market Cap
$767.62M
Shares
32.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.35
Open$22.98
Day$22.36–23.99
52W close$5.65–28.53
Avg vol 30d223K
Short int1.8M · 5.7% float · 7.4d
Short vol36%
Last earningsJun 22, 2026
DataFeb 2022–Aug 2026
Filing10-Q · Aug 4
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+112%
above
Price vs 50-day avg
+23%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
77%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+164%
trailing
YTD return
+209%
this year
Relative strength
+152%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+32% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
5.66% of float · ▲ +21.9% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
83 holders — near 3-yr high, broad support
Squeeze score
86
high risk · 0–100
Fundamentals
EPS growth
−19%
Y/Y
Balance sheet
$31.6M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+112%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
77%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $19 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+32% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
5.66% of float · ▲ +21.9% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
83 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $23 · 77%
Range high $29
vs 200-day avg +112%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVCT
this stock
Nuvectis Pharma, Inc.
|
$767.62M | +209.3% | — | — | 5.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.4% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVCT | +21.4% | +15.9% | +163.5% | +8.5% | +209.3% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +23.4% | +12.6% | +152.4% | +6.4% | +197.4% |
Key facts
CIK
1875558
CUSIP
67080T108
13F (30d)
78 filings
78 filers
Visit website
Investor relations